Latest News

• Brain Tumor Awareness Month Webinar Series        

  To watch our GBM AGILE trial webinar from last week, click HERE.

  Coming up next:
  Tuesday May 14, 2024 (7pm EST) Duke Clinical Trials, Dr. Annick Desjardins

  Thursday May 16, 2024 (7pm EST) Results from University of Michigan high-grade glioma trial, Dr. Maria Castro and Dr. Pedro Lowenstein

  Monday May 20, 2024 (2pm EST) ReSPECT GBM Phase 2 trial, Dr. Andrew Brenner and Dr. Marc Hendrick

  Thursday May 23, 2024 (6pm EST) Empowering Brain Tumor Patients, Dr. Isabelle Germano, Dr. Kevin Elmore and Dr. Stanislav Lazarev (Hosted by Icahn School of Medicine at Mount Sanai)

  Wednesday May 29, 2024 (7pm EST) IMVAX Phase 2b trial, Dr. Brad Zacharia

  
  
• Minnesota Brain Tumor 5k Announces 15th Annual Fun Walk/Run        

  As part of the National Walk to End Brain Tumors, the 15th annual Minnesota Brain Tumor 5K is coming up on May 19th. This is a great event for everyone in the Minnesota area. All funds raised go directly to the Musella Foundation and will be used exclusively for brain tumor research!

  
  
• CIRM Awards $11.8 Million Grant for Clinical Trial in High-Grade Glioma Including Glioblastoma Using DB107, a Novel DGM7 Genetic Biomarker-Guided Gene Therapy        

  Very exciting news! DB107 is the new name for a previously tested 2-drug combination (Toca 511 + Toca FC). The Musella Foundation was an early supporter of the treatment via grants, back when the drugs were owned by a company called Tocagen. Early trials did well. The large Phase 3 trial failed, but there was a small subset of very successful responders. At first, nobody knew why only some patients benefited, but the company that now owns the drugs (Denovo) discovered a new biomarker they believe accounts for the favorable response. Based on this discovery, new trials will be launched to confirm the treatment helps patients who have the relevant 'DGM7' biomarker. This large grant will help fund the trials, and we hope to see enrollment opening soon!